【聚焦ADC&CGT】与阿斯利康/第一三共/卫材/诺华等国际重磅嘉宾一聚！Asia BIO • 新加坡站-8月14-15日

来源：网络 2025-07-25 15:49

Asia BIO Innovation Summit 作为亚洲地区生物医药行业的高端峰会，2025年在新加坡、成都以及深圳三地召开系列峰会，本次Asia BIO • 新加坡站将于8月14日-15日召开

Asia BIO Innovation Summit 2025 is one of the premier industry-focused events in Asia and focus on the hottest topics of ADC and CGT.This summit aims to build an academic exchange platform for excellent ADC and CGT companies in Asia and around the world to showcase the latest technologies and research results, Promote offine international technical exchanges and business cooperation opportunities.

Asia BIO Innovation Summit 作为亚洲地区生物医药行业的高端峰会，2025年在新加坡、成都以及深圳三地召开系列峰会，本次Asia BIO • 新加坡站将于8月14日-15日召开，聚焦ADC与CGT两大前沿领域，将涵盖从临床前研发、质量控制、临床策略、生产工艺等全流程环节，预计将吸引超过30+演讲嘉宾、15+主流展商以及300+观众参与。

ADC Innovation Asia 2025

▼ Rise of ADC in Asia - August 14

09:00

Strategic Approaches to ADC Bioanalysis: Navigating In Vivo Biotransformation and Incurred Sample Challenges

Daiichi Sankyo，Senior Director，Ling He

09:30

Development of First-in-class, Clinical Stage ADC EBC-129 for Solid Malignancies

EDDC，Asset Development Lead，Veronica Diermayr

10:00

Open for Sponsor

10:30

Coffee Break & Networking

10:50

VelaVigo: An Innovative Biotech Focusing on FIC and BIC Multi-Specific ADC and TCE

VelaVigo，CEO，Jing Li

11:20

TBD

AstraZeneca，Managing Director，Hadassah Sade

11:50

Broad-Spectrum Efficacy of CEACAM6-Targeted ADC with BBT Protein Degrader in Solid Cancer Models

Eisai，Scientist，Hiroyuki Kogai

12:20

Panel Discussion: ADC Deals in Asia

Next Generation ADCs

14:00

Novel Bispecific and FIG ADCs: a Product-oriented Approach

1)Strategic thinkings about the future of ADC sector;

2)How to differentiate and position in this increasingly competitive landscape;

3)How to balance the risks and benefits brought to drugability by target/target pair selection and technology innovation.

Innolake Biopharm，Co-Founder，Robert Chen

14:30

Open for Sponsor

15:00

Development of AxcynDOT™ as a Next-Generation ADC Payload Technology

1）Overview of current and next generation of ADCs

2）AxcynDOTTM: Potential game-changer technology

3）Preclinic discovery of AT65474

Axcynsis Therapeutics，CEO，Bin Zou

15:30

Coffee Break & Networking

15:50

EDDC

16:20

Developing High-Efficacy, Stable ADCs with High DAR (8 or 12) and Dual Payloads Using a Versatile Drug Bundle Technology Platform

1）TE Meds'Cutting-Edge Drug-BundleTechnology

2）Introducing CHO-TEM: A Platform forHigh-DAR ADC Development

3）Unveiling TE-1182:An Innovative Dual-Payload ADC

T-E Meds, Manager of T-E Drug Design, Cédric Grauffel

16:50

Strategies and Challenges for Next-Generation ADC Development at ABL Bio

ABL Bio，Head of R&D，Weon Kyoo You

17:20

Panel Discussion: Next Gen ADC Design

19:00-21:00

Reception dinner

CGT Innovation Asia 2025

▼ CGT Innovation in Asia - August 15

09:00

T Cell Therapy: A Tumor-Agnostic Patient-Centric Strategy

MD Anderson Cancer Center, Professor, Cassian Yee

09:30

Tackling the bottleneck of cell based therapy, transformation from ex vivo to in vivo gene editing by open innovation

Nanjing IASO Biotechnology，Chief Innovation and Investment Officer，Xavier Xie

10:00

From Autologous CAR-T to Allo Cell Therapy

1）Challenges of autologous CAR T

2）Next generation Allo cell therapies

3）From cancer treatment to autoimmune diseases

Tikva Allocell，CEO & Founder MD, FACP，Ivan Horak

10:30

Coffee Break & Networking

10:50

Immunotherapy for Cancer Cure and Beyond – A Historical Mission

Biosyngen，President，Hao Shen

11:20

NVC-001, leveraging mechanobiology insightsto treat LMNA dilated cardiomyopathy（CMNA DCM）

1）Overview ofLMNA DCM and why there arecurrently no effective therapies for it

2）Nuevocor designed NVC-001 to target themechanobiology root cause of disease

3）Preclinical data demonstrating significantsurvival benefits and safety data

Nuevocor，CEO，Yann Chong Tan

11:50

Solid tumor armored CAR-T development

Elpis，Founder and CEO，Yan Chen

12:20

Panel Discussion: Cell and Gene Therapy Breakthrough in Asia

'Off-the-shelf' Allogeneic Cell Therapy / Stem Cells / iPSCs

14:00

TBD

Lee Kong Chian School of Medicine，Associate Professor，Yen Choo

14:30

hPSCs for Studying Diabetes and Cell Replacement Therapy

Betalife，Scientific Co-Founder & Advisor，Adrian Teo

15:00

SimnovaBio

15:30

Coffee Break & Networking

15:50

Enhancing Therapeutic Impact: Integrating Co-stimulatory Signaling in TGR-T Therapies for Solid Tumors

1）Unique advantages of TCR-T cell therapy

2）Potential for enhancing TCR-T therapy efficacythrough integration with co-stimulatory signalingapproaches

3）Strategic considerations for incorporating co-stimu-latory signaling, with a focus on molecular designs ofTCR-based therapies, such as TCR-CAR-T

Imgen BioSciences，President，Wendell Yang

16:20

Versatile Engineering Platform for Anti-Cadherin 17 CAR-T/NK Cell-based Cancer Therapy

1）CDH17 as a promising target for cancer immunotherapy

2）Arbele’s proprietary mRNA CAR-T/NK platform

3）Preclinical development of ARB001

Arbele Bio，CTO，Tong Wong

16:50

Non-Viral BaAb Armed-T Therapy

1）The Armed-T platform provides a novelmethod for T cell therapies, highlighting keyadvantages such as high purity, virus-free pro.cesses, and quick large-scale production

2）Armed Tcells exhibit diverse features thathelp overcome the immunosuppressive tumomicroenvironment

3）The Armed-T platform is designed to behighly adaptable, enabling it to target a broadrange of cancers

CytoArm，CEO，Kuo-Hsiang Chuang

17:20

Development of Bispecific Extracellular Vesicles for Cancer Immunotherapy

National University of Singapore，Associate Professor，Le Thi Nguyet Minh

17:50

FIC novel target immunotherapies for the treatment of cancer

Eximmium，Founder & Group CEO，Lietao Li